Advertisement

Picture [iito] Männer Ballett 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1963 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED 2021-01-11
Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies 2021-01-07
Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare 2021-01-05
Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare 2021-01-05
Cellectis–SEVERAL: investment, 202012 underwritten public offering of ADSs $100m+15m ANNOUNCED + WITHDRAWN 2020-12-14
InnoSkel–Consilium: public relations, 202012 service existent by Consilium Strategic Communications 2020-12-14
InnoSkel–Jeito Capital: investment, 202012 financing round Series A totalling €20m incl co-lead investor Jeito Capital 2020-12-14
InnoSkel–Région Sud (FR): investment, 202012 financing round Series A totalling €20m incl co-investor Région Sud Investissement 2020-12-14
InnoSkel–SEVERAL: investment, 202012 financing round Series A €20m co-led by Jeito Capital + Vida Ventures 2020-12-14
InnoSkel–Turenne: investment, 202012 financing round Series A totalling €20m incl co-investor The Turenne Group 2020-12-14
InnoSkel–Vida Ventures: investment, 202012 financing round Series A totalling €20m incl co-lead investor Vida Ventures 2020-12-14
MaaT Pharma–Céleste Management: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor Céleste Management 2020-12-01
MaaT Pharma–France (govt): investment, 202012 financing round Series B extension totalling €7.35m incl new + lead investor PSIM Fund 2020-12-01
MaaT Pharma–SEVERAL: investment, 202012 financing round Series B extension €7.35m led by Bpifrance bringing total Series B to €25.35m 2020-12-01
MaaT Pharma–SkyViews Life Science: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor SkyViews Life Science 2020-12-01
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED 2020-12-01
Emergence Therapeutics–High-Tech Gründerfonds: investment, 202011 follow-on seed financing round incl lead investor HTGF 2020-11-25
Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF 2020-11-25
AlgoTherapeutix–SEVERAL: investment, 202011 financing round Series A €12m led by Bpifrance InnoBio 2 fund + co-investor Omnes 2020-11-24
Catamaran Bio–SEVERAL: investment, 202011 financing round Series A $42m co-led by Sofinnova Partners + Lightstone Ventures 2020-11-23
Catamaran Bio–Sofinnova: investment, 202011 financing round Series A $42m incl co-lead investor Sofinnova Partners 2020-11-23
Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund 2020-11-23
Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo 2020-11-23
Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund 2020-11-23
Myricx Pharma–SEVERAL: investment, 202011 seed financing round £4.5m with Sofinnova Partners + Brandon Capital Partners 2020-11-16
Myricx Pharma–Sofinnova: investment, 202011 seed financing round totalling £4.5m incl investor Sofinnova Partners 2020-11-16
Jeito Capital–Sanofi: investment, 202011 investment €50m by Sanofi 2020-11-13
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings 2020-11-03
Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures 2020-11-02
Eurofins–Waters: mass spectrometer, 202011 supply existent Radian ASAP System beta customer Eurofins Forenscis Teddington 2020-11-02
Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) 2020-11-02
GenSight Biologics–Arix Bioscience: investment, 202010 private placement totalling €25m incl co-lead investor Arix Bioscience 2020-10-22
GenSight Biologics–France (govt): investment, 202010 private placement totalling €25m incl €1m from existing + co-investor Bpifrance Investissement 2020-10-22
GenSight Biologics–Invus Group: investment, 202010 private placement totalling €25m incl co-lead investor Invus 2020-10-22
GenSight Biologics–SEVERAL: investment, 202010 private placement €25m led by Arix Bioscience + Invus + Sofinnova Partners 2020-10-22
GenSight Biologics–Sofinnova: investment, 202010 private placement totalling €25m incl €4.5m from existing + co-lead investor Sofinnova Partners 2020-10-22
SparingVision–4BIO Ventures: investment, 202010 financing round totalling €44.5m incl new + co-lead investor 4BIO Capital 2020-10-21
SparingVision–Consilium: public relations, 202011 service existent by Consilium Strategic Communications 2020-10-21
SparingVision–Foundation Fighting Blindness: investment, 202010 financing round totalling €44.5m incl existing + co-investor FFB 2020-10-21
SparingVision–France (govt): investment, 202010 financing round totalling €44.5m incl existing + co-investor Bpifrance 2020-10-21
SparingVision–Jeito Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Jeito Capital 2020-10-21
SparingVision–SEVERAL: investment, 202010 financing round €44.5m led by 4BIO Capital + UPMC Enterprises 2020-10-21
SparingVision–Torreya: financial services, 202010 supply service Torreya Capital LLC acted as excl placement agent for €44.5m offering 2020-10-21
SparingVision–Univ Pittsburgh: investment, 202010 financing round totalling €44.5m incl new + co-lead investor UPMC Enterprises 2020-10-21
SparingVision–Ysios Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Ysios Capital 2020-10-21
Carmat–France (govt): grant, 202010– grant €13m national innovation funding for clinical study of artificial heart in France from Health Ministry 2020-10-12
Priothera–Earlybird: investment, 202010 financing round Series A totalling €30m incl co-investor Earlybird Venture Capital 2020-10-12
Priothera–Fountain Healthcare Partners: investment, 202010 financing round Series A totalling €30m incl lead investor FHP 2020-10-12
Priothera–Huntsworth: public relations, 202010 service existent by Citigate Dewe Rogerson 2020-10-12
Priothera–Kyorin: mocravimod, 202010c acquisition of mocravimod from Kyorin Pharmaceutical Co Ltd 2020-10-12
Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap 2020-10-12
Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners 2020-10-12
Priothera–Tekla Capital: investment, 202010 financing round Series A totalling €30m incl co-investor funds managed by Tekla Capital Management LLC 2020-10-12
Federation Bio–BPCE: investment, 202010 financing round Series A totalling $50m incl new + co-investor Seventure Partners/Health for Life Capital 2020-10-06
Federation Bio–SEVERAL: investment, 202010 financing round Series A $50m led by Horizons Ventures + incl Seventure Partners + Venrock + Altitude 2020-10-06
Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis 2020-10-06
BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED 2020-10-02
Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth 2020-10-01
Kurma–SEVERAL: investment, 202009 first closing €50m of Kurma Diagnostics 2 Fund (KDx2) 2020-09-29
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures 2020-09-25
Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund 2020-09-23
Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures 2020-09-17
ImCheck Therapeutics–Bellevue: investment, 202009 financing round Series B extension €6m from BB Pureos Bioventures bringing total Series B to €54m 2020-09-15
Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020 2020-09-14
Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital 2020-09-14
Neogene Therapeutics–SEVERAL: investment, 202009 financing round Series A $110m co-led by EcorR1 Capital + Jeito Capital + Syncona 2020-09-14
Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares 2020-08-19
Principia Biopharma–Sanofi: investment, 202008– acquisition $3.68b cash tender offer at $100/share 2020-08-17
Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED 2020-08-13
T-Knife–SEVERAL: investment, 202008 financing round Series A €66m co-led by Versant Ventures + RA Capital 2020-08-06
DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital 2020-07-29
Enthera–SEVERAL: investment, 202007 financing round Series A €28m co-led by Sofinnova Partners + AbbVie Ventures 2020-07-28
Enthera–Sofinnova: investment, 202007 financing round Series A totalling €28m incl existing + co-lead investor Sofinnova Partners 2020-07-28
Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners 2020-07-21
Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF 2020-07-21
Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina 2020-07-14
Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications 2020-07-08
Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties 2020-07-08
Citryll–BPCE: investment, 202007 financing round Series A totalling €18.5m incl new + lead investor Seventure incl its Health for Capital II fund 2020-07-02
Citryll–SEVERAL: investment, 202007 financing round Series A €18.5m led by Seventure + co-led by BioGeneration Ventures 2020-07-02
Lysogene–Weizmann Institute: gene therapy, 202007– collab research + license option AAV gene therapy for Gaucher + Parkinson diseases 2020-07-01
Resolution Spectra Systems–Merck (DE): investment, 202007 acquisition €na of Resolution Spectra Systems by Merck 2020-07-01
Enterome–BPCE: investment, 202006 financing round Series E €na incl existing investor Seventure Health for Life Capital 2020-06-25
Enterome–Nestlé: investment, 202006 financing round Series E €na incl existing investor Nestlé Health Science 2020-06-25
Enterome–Omnes Capital: investment, 202006 financing round Series E €na incl existing investor Omnes Capital 2020-06-25
Enterome–Principia SGR: investment, 202006 financing round Series E €na incl existing investor Principia 2020-06-25
Enterome–SEVERAL: investment, 202006 financing round Series E €na with existing plus new investors SymBiosis LLC + Takeda Pharma 2020-06-25
Enterome–SymBiosis LLC: investment, 202006 financing round Series E €na incl new investor SymBiosis LLC 2020-06-25
Enterome–Takeda: investment, 202006 financing round Series E €na incl new investor Takeda Pharmaceutical Co Ltd 2020-06-25
RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion 2020-06-22
Kaia Health–SEVERAL: investment, 202006 financing round Series B $26m led by Optum Ventures + Idinvest + capital300 2020-06-18
DiogenX–Advent France Biotechnology: investment, 202006 seed financing round totalling €4.5m incl investor Advent France Biotechnology 2020-06-16
DiogenX–Andrew Lloyd Associates: public relations, 202006 service existent by ALA 2020-06-16
DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF 2020-06-16
DiogenX–Juvenile Diabetes Research Foundation: investment, 202006 seed financing round totalling €4.5m incl investor JDRF T1D Fund 2020-06-16
DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund 2020-06-16
eTheRNA–BNP Paribas: investment, 202006 financing round Series B totalling €34m incl new investor BNP Paribas Fortis Equity 2020-06-16
MedinCell–SEVERAL: investment, 202006 capital increase €15.6m from French + international investors 2020-06-16
Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2 2020-06-16
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page



Advertisement

Picture [iito] Plain Stupid Simple 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top